Cargando…
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by det...
Autores principales: | de Assis, Rafael R., Jain, Aarti, Nakajima, Rie, Jasinskas, Algis, Felgner, Jiin, Obiero, Joshua M., Adenaiye, Oluwasanmi, Tai, Sheldon, Hong, Filbert, Norris, Philip J., Stone, Mars, Simmons, Graham, Bagri, Anil, Schreiber, Martin, Buser, Andreas, Holbro, Andreas, Battegay, Manuel, Hosimer, Philip, Noesen, Charles, Milton, Donald K., Davies, D. Huw, Contestable, Paul, Corash, Laurence M., Busch, Michael P., Felgner, Philip L., Khan, Saahir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217240/ https://www.ncbi.nlm.nih.gov/pubmed/32511302 http://dx.doi.org/10.1101/2020.04.15.043364 |
Ejemplares similares
-
Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray
por: de Assis, Rafael R., et al.
Publicado: (2021) -
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
por: Khan, Saahir, et al.
Publicado: (2020) -
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray
por: Assis, Rafael, et al.
Publicado: (2021) -
Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study
por: Khanna, Nina, et al.
Publicado: (2020) -
Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients
por: Weisser, Maja, et al.
Publicado: (2022)